CSIG-08. MASS CYTOMETRY IDENTIFIES LOCATION-SPECIFIC TUMOR POPULATION ASSOCIATED WITH CLINICAL PROGRESSION IN GLIOBLASTOMA

Abstract Recent advances in single cell expression technology have allowed us to appreciate the complexity tumoral heterogeneity of solid tumors such as glioblastoma (GBM), which remains uniformly fatal despite aggressive therapies. Currently, there is no knowledge about identities and functional characteristics different populations. To this end, we created a 28-marker mass cytometry panel composed signaling markers, including phospho-proteins, lineage markers that been associated with GBM or are considered putative cancer stem markers. We evaluated lines established from core edge areas same patient validated be functionally RNA vivo experiments. found clusters shared by cells both regions well region-specific ones. In order better characterize these, used marker enrichment modeling (MEM) generated machine-readable labels. These were compared MEM labels after using cluster primary samples newly diagnosed recurrent patients. Similarly, obtained patients clinical trial treated capecitabine had positive negative responses. Clusters higher proportion correlated responses chemotherapy. Initial analyses also done correlating immune tumor samples. Edge characterized CD44+ SOX2+ Nestin+ population. Treatment temozolomide irradiation results an increase population vitro. currently conducting studies validate tumor-immune interactions. Our exploit underscore pathways preferentially use populations affect goal establishing therapeutic efforts extend survival.